 |
|||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||
|
Axelar Initiates Phase I/II Clinical Trial on Cancer Patients With the New Anti-Cancer Drug AXL1717 Stockholm, Sweden 2008-06-17 Axelar AB today announced that the company recently has initiated a phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717, an insulin-like growth factor-1 (IGF-1) receptor inhibitor. The phase I/II clinical trial is primarily.
|
||||||||||||||||||||||||||||||||||||||||||||
Press release